ImaginAb Roundtable 2

Explore the value that CD8 ImmunoPET may offer in drug pipeline development in immunotherapy clinical trials

Join the discussion with our expert panel from multi-national pharmaceutical companies to find out more

31st March 2022

10:00 - 11:00 PST

ImaginAb, a market leading global biotechnology company, focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT) is hosting a series of virtual breakfast roundtable events.

Join the second of these sessions to explore the value that CD8 ImmunoPET may offer in drug pipeline development in immunotherapy clinical trials.


10.00 – 10.10 am
Welcome & Introduction
Dr. Ian Wilson
10.10 – 10.30 am
Pfizer’s pharmaceutical perspective of 89Zr-Df-Crefmirlimab as a potential clinical imaging biomarker for the assessment of CD8+ T cell infiltration for novel immunotherapies in drug development
Dr. Kevin Maresca
10.30 – 10.55 am
Q&A session
Dr. Patricia Cole
Dr. Kevin Maresca
Dr. Andrea Thiele
10.55 – 11.00 am
Meeting Close
Dr. Ian Wilson
11.00 - 12.00 pm
Optional breakout session to answer specific questions
Matt Ennis and Gregory Frank

Guest speaker - Dr. Kevin Maresca

  • Head of PET & Molecular Imaging, Early Clinical Development Group - Pfizer

Dr. Kevin Maresca is the Head of PET and Molecular Imaging within Pfizer’s Early Clinical Development Group. The PET and Molecular Imaging Group serves across all Pfizer therapeutic areas, with a broad scope that includes novel preclinical ideas to POC and late phase clinical trials. The model employed utilizes key collaborations to mainly outsource data generation for preclinical and clinical studies, using both routine and novel methodology. Dr. Maresca is a multi-faceted PET Imaging scientist with more than 20 years of pharmaceutical drug discovery and development experience in the area of targeted small molecules, peptides, and biologic-based drug product candidates, with over 50 publications and 10 patents.

Kevin joined Pfizer from Molecular Insights Pharmaceuticals (Cambridge, MA) where he worked for 14 years, having served as Director of Radiochemistry and Production. Overall, he has been involved with the advancement of >15 radiolabeled compounds into clinical trials, including the development and optimization of the drug product 99mTc-MIP-1404, a potent prostate specific membrane antigen (PSMA) inhibitor for the diagnostic imaging of metastatic prostate cancer. Kevin received his PhD in Chemistry from Syracuse University, and was a Postdoctoral Fellow at Harvard Medical School, Brigham and Woman’s Hospital.

Round table


Dr. Ian Wilson - Roundtable Moderator

CEO of ImaginAb

With over 25 years of experience in development of in vivo medical diagnostics and imaging medical devices, he is a highly established and influential member of the industry and has built an enviable skill-set over the years through a number of significant healthcare roles.

It’s this diverse portfolio of skills, along with his aspirational vision of growing ImaginAb to transform the healthcare and biotechnology industry that has led Dr. Wilson to accelerate ImaginAb’s business presence and performance.


Dr. Patricia Cole - Panel Member

Executive Director - Head, Clinical Imaging Strategy. Strategic Business Unit Oncology (Bayer U.S)

Patricia E. Cole, PhD, MD is an Executive Director and the Head of Clinical Imaging Strategist within the Oncology Strategic Business Unit at Bayer Pharmaceuticals. In this role, Dr. Cole ensures that oncology clinical programs are using appropriate and state of the art imaging techniques and is involved in the strategic planning, execution and interpretation of imaging biomarkers and technologies in oncology clinical trials.

Dr. Cole has had over 20 years of experience in the pharmaceutical and imaging CRO industries with a focus on (a) strategies for use of imaging biomarkers in drug development and (b) the implementation of imaging biomarkers in clinical trials across therapeutic areas using PET, MRI , CT and ultrasound technologies. Dr. Cole is a board-certified radiologist with subspecialty qualification in cardiovascular and interventional radiology. She completed her MD degree at Albert Einstein College of Medicine, and her radiology residency and fellowship at NY Hospital-Weil Cornell Medical Center. Her radiology faculty positions included Memorial Sloan Kettering Cancer Center and Yale-New Haven Medical Center. She also holds a PhD in biophysical chemistry and completed postdoctoral work in molecular biology and MR spectroscopy.


Dr. Andrea Thiele - Panel Member

Transl. Medicine & Clin Pharmacology (Boehringer Ingelheim Pharma GmbH & Co. KG)

Andrea Thiele is a biologist by training and has been working in the field of PET ligand development for 17 years. As a Principal Scientist at Schering AG and Bayer AG, she was developing PET ligands for assessment of neuroinflammation, and participated in the development of NeuraCeq ®.

Currently, she is employed as a Principal Clinical Imaging Lead in the Translational Medicine and Clinical Pharmacology Department at Boehringer Ingelheim. In her function, she is responsible for development of the imaging strategy in oncology, implementation of imaging biomarkers into development trials for novel oncological drugs and exploring novel imaging biomarkers to enable their use in clinical trials.

Register today for the Roundtable